Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

How will PCSK9 inhibitors be used in real world clinical practice?

Prof Anthony Wiezbicki, Guy’s and St Thomas’ NHS Foundation Trust, London UK gives his view on how these novel PCSK9 therapeutics will be used in real-world clinical settings.

How will PCSK9 inhibitors be used in practice?
www.pcsk9forum.org/how-will-pcsk9-inhibitors-be-used-in-practice/

What are the patient priorities for PCSK9 inhibitors?
www.pcsk9forum.org/what-are-the-patient-priorities-for-pcsk9-inhibitors/

FH: Start treatment early: Maximise benefit
www.pcsk9forum.org/start-treatment-early-maximise-benefit/

The role of PCSK9 inhibitors in FH
www.pcsk9forum.org/dr-dirk-blom-south-africa-the-role-of-pcsk9-inhibitors-in-fh/

Weighing the cost versus benefit of PCSK9-targeted therapy
www.pcsk9forum.org/weighing-the-cost-versus-benefit-of-pcsk9-targeted-therapy/

PCSK9 INHIBITION: New Therapies in Cardiovascular Risk Reduction
www.pcsk9forum.org/pcsk9-inhibition-new-therapies-in-cardiovascular-risk-reduction/

Impact on CHD risk:
www.pcsk9forum.org/acc-2015-what-do-the-osler-and-odyssey-data-really-show-expert-analysis-from-professor-derick-raal/

Impact on guidelines?
www.pcsk9forum.org/high-intensity-cholesterol-lowering-therapy-versus-high-intensity-statin-therapy/